Compare Quest Diagnostics Inc (DGX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Warner Music Group Corp — how do they compare? Quest Diagnostics Inc trades at $230.76 (market cap $25.48B), while Warner Music Group Corp trades at $28.88 (market cap $15.12B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Warner Music Group Corp pays the higher dividend (2.77%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Warner Music Group Corp for 96 Days on average.
| DGX | WMG | |
|---|---|---|
Market Cap | $25.48B | $15.12B |
Volume | 941,866 | 2,966,414 |
Sector | Health | Media |
52-Week High | $247.45 | $34.72 |
52-Week Low | $173.49 | $23.65 |
Typical Hold Time | 56 Days | 96 Days |
Enterprise Value | $31.23B | $19.42B |
Dividend Yield | 1.49% | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
WMG trades at $28.875, up 2.54% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.38, beating expectations, and has a strong analyst consensus of 'Buy' with a $39.50 price target. Recent news highlights AI partnerships and licensing renewals as growth catalysts.
Outlook remains positive due to streaming growth and AI initiatives, but risks include competitive pressures and margin volatility. The stock offers upside potential from current levels if execution continues, though investor caution is warranted near-term given elevated RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
